Abstracts from the ASENT 2006 Annual Meeting March 8–11, 2006

Abstracts from the ASENT 2006 Annual MeetingMarch 8–11, 2006 Duloxetine in the Management of DiabeticPeripheral Neuropathic Pain: Response Profile Y Pritchett, B McCarberg, J Watkin, A Chappell,M Robinson Eli Lilly and Company and University of California—San Diego Introduction: Analyses examine the response rate at end-point, as well as time course of response, in patients receivingduloxetine for management of diabetic peripheral neuropathicpain (DPNP). Methods: Data were pooled from 3 double-blind, random-ized, placebo-controlled 12-week trials in patients with DPNP 6 months duration, and without depression. Study 1 ( N 457) compared duloxetine 20 mg once daily (QD), 60 mg QD,60 mg twice daily (BID), and placebo; Studies 2 ( N 334) and3( N 348) compared duloxetine 60 mg QD and 60 mg BIDwith placebo. Ethics committees approved the study protocol inaccordance with Declaration of Helsinki principles. Patientsprovided written informed consent prior to study participation.Treatment response was defined a priori as 30% reduction inthe primary efficacy measure, 24-hour average pain severity.Analysis was replicated using alternative criteria (50% reduc-tion or 2-point reduction).